AR025692A1 - VECTORES ADENOVIRALES RECOMBINANTES, UN PROCESO PARA SU MANUFACTURA, UNA COMPOSICIoN FARMACEUTICA QUE LOS COMPRENDE Y SU USO PARA LA MANUFACTURA DE UN MEDICAMENTO EN EL TRATAMIENTO DE DIVERSOS TIPOS DE FIBROSIS HEPÁTICA, RENAL, PULMONAR Y CICATRICES HIPERTROFICAS - Google Patents
VECTORES ADENOVIRALES RECOMBINANTES, UN PROCESO PARA SU MANUFACTURA, UNA COMPOSICIoN FARMACEUTICA QUE LOS COMPRENDE Y SU USO PARA LA MANUFACTURA DE UN MEDICAMENTO EN EL TRATAMIENTO DE DIVERSOS TIPOS DE FIBROSIS HEPÁTICA, RENAL, PULMONAR Y CICATRICES HIPERTROFICASInfo
- Publication number
- AR025692A1 AR025692A1 ARP000104867A ARP000104867A AR025692A1 AR 025692 A1 AR025692 A1 AR 025692A1 AR P000104867 A ARP000104867 A AR P000104867A AR P000104867 A ARP000104867 A AR P000104867A AR 025692 A1 AR025692 A1 AR 025692A1
- Authority
- AR
- Argentina
- Prior art keywords
- fibrosis
- mmp
- manufacture
- therapeutic
- vectors
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 2
- 230000002440 hepatic effect Effects 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 230000002685 pulmonary effect Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 8
- 206010016654 Fibrosis Diseases 0.000 abstract 6
- 230000004761 fibrosis Effects 0.000 abstract 6
- 230000001225 therapeutic effect Effects 0.000 abstract 6
- 238000001415 gene therapy Methods 0.000 abstract 2
- 210000004185 liver Anatomy 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 abstract 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 abstract 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 abstract 1
- 102100027995 Collagenase 3 Human genes 0.000 abstract 1
- 108050005238 Collagenase 3 Proteins 0.000 abstract 1
- 206010023330 Keloid scar Diseases 0.000 abstract 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 abstract 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 abstract 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 abstract 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 abstract 1
- 102100030411 Neutrophil collagenase Human genes 0.000 abstract 1
- 101710118230 Neutrophil collagenase Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 108700026244 Open Reading Frames Proteins 0.000 abstract 1
- 101700026522 SMAD7 Proteins 0.000 abstract 1
- 206010050207 Skin fibrosis Diseases 0.000 abstract 1
- 102000049873 Smad7 Human genes 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 230000001969 hypertrophic effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 201000002793 renal fibrosis Diseases 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10241—Use of virus, viral particle or viral elements as a vector
- C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Un vector adenoviral recombinante, que comprende un genoma adenoviral del cual se han delatado los marcos de lectura abiertos E1 y/o E3, pero que retienela secuencia suficiente para que dicho vector adenoviral sea capaz de replicarse in vitro,conten iendo adicionalmente dicho vector, un gen terapéutico o unasecuencia de ADN de interés regulada por promotores ubicuotos y/o promotores especificos de tejido, que codifica para proteínas terapéuticas utiles en eltratamiento de la fibrosis, unproceso para su preparacion y composicion farmacéutica que los comprenden. Se propone el uso de terapia génica para suaplicacion en el tratamiento de diversas fibrosis en humanos. El objetivo es la utilizacion de genes terapéuticos, específicamentedirigido s a organosblanco para revertir y/o prevenir el desarrollo del proceso que cursa con fibrosis. La potencial aplicacion de terapia génica a pacientes con fibrosis y/ocirrosis dependerá en buena parte del envío exitoso de genes que codifiquenpara prot eínas terapéuticas a hígado con fibrosis extensa y que estos genes quecodifiquen para proteínas MMP-8 latente y activa, MMP-1, MMP-2, MMP-9 y MMP-13; uPA silvestre y/o modificado (o su version truncada); receptor truncado tipo IIde TGF-beta y Smad7 s ean dirigidos por adenovirus y/u otros vectores recombinantes que no transduzcan (infecten) otros organos de la economía. Los adenovirusrecombinantes (AdR) son vectores altamente eficientes para la transduccion de genes terapéuticos adiversas célula s blanco. Hemos probado que se pueden llevargenes a hígados cirroticos. El envío de genes terapéuticos mediante dichos vectores adenovirales y otros vectores recombinantes se podrá realizar utilizandoliposomas (DOTMA) cationicos yanionicos. Asimismo , proponemos el uso de estos vectores para que de igual manera sea aplicada a: fibrosis renal, fibrosispulmonar, cicatrices hipertroficas y keloides (fibrosis de la piel), y otros tipos de fibrosis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MXPA/A/1999/008515A MXPA99008515A (es) | 1999-09-17 | Vectores adenovirales recombinantes y su utilidad en el tratamiento de diversos tipos de fibrosis hepática, renal, pulmonar y cicatrices hipertróficas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR025692A1 true AR025692A1 (es) | 2002-12-11 |
Family
ID=19745116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000104867A AR025692A1 (es) | 1999-09-17 | 2000-09-15 | VECTORES ADENOVIRALES RECOMBINANTES, UN PROCESO PARA SU MANUFACTURA, UNA COMPOSICIoN FARMACEUTICA QUE LOS COMPRENDE Y SU USO PARA LA MANUFACTURA DE UN MEDICAMENTO EN EL TRATAMIENTO DE DIVERSOS TIPOS DE FIBROSIS HEPÁTICA, RENAL, PULMONAR Y CICATRICES HIPERTROFICAS |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20030003077A1 (es) |
| EP (1) | EP1221490B1 (es) |
| JP (1) | JP4173663B2 (es) |
| AR (1) | AR025692A1 (es) |
| AU (1) | AU7322600A (es) |
| CA (1) | CA2385538C (es) |
| CO (1) | CO5420199A1 (es) |
| DE (2) | DE1221490T1 (es) |
| ES (1) | ES2183752T3 (es) |
| HK (1) | HK1049860B (es) |
| PE (1) | PE20010610A1 (es) |
| WO (1) | WO2001021761A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2446946A1 (en) * | 2001-05-09 | 2002-11-14 | Anges Mg, Inc. | Gene transfer of angiogenic factor for skin disease |
| WO2003086278A2 (en) | 2002-04-05 | 2003-10-23 | Board Of Regents, The University Of Texas System | Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions |
| US9388427B2 (en) | 2002-12-02 | 2016-07-12 | Biovec, Llc | In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors |
| US20050036988A1 (en) * | 2003-05-28 | 2005-02-17 | Ruian Xu | Compositions and methods for preventing and treating liver cirrhosis |
| CN1898379A (zh) * | 2003-12-23 | 2007-01-17 | 先灵公司 | 生产在无血清的培养基悬浮培养中稳定的a549细胞系的方法 |
| JP4764872B2 (ja) * | 2004-03-30 | 2011-09-07 | インダストリー−アカデミック コオペレイション ファウンデーション，ヨンセイ ユニバーシティ | リラクシン遺伝子を含む遺伝子伝達システム及びリラクシンを用いた薬剤学的組成物 |
| US20080107630A1 (en) * | 2006-04-10 | 2008-05-08 | New York University | Human matrix metalloproteinase-8 gene delivery enhances the oncolytic activity of a replicating adenovirus |
| KR102272213B1 (ko) | 2014-07-08 | 2021-07-01 | 삼성전자주식회사 | 표적화 부위, 절단 부위, 및 세포막 투과 부위를 포함하는 융합 단백질 및 그의 용도 |
| WO2022047119A1 (en) * | 2020-08-28 | 2022-03-03 | Carisma Therapeutics Inc | Modified immune cells for fibrosis and inflammation |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
| US5614395A (en) * | 1988-03-08 | 1997-03-25 | Ciba-Geigy Corporation | Chemically regulatable and anti-pathogenic DNA sequences and uses thereof |
| US5585362A (en) * | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5240846A (en) * | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
| NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| WO1993025673A1 (en) * | 1992-06-04 | 1993-12-23 | The Regents Of The University Of California | In vivo gene therapy with intron-free sequence of interest |
| GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
| DE4339922C1 (de) * | 1993-09-03 | 1994-10-06 | Max Planck Gesellschaft | Vektor für Leber-Gentherapie |
| US6686198B1 (en) * | 1993-10-14 | 2004-02-03 | President And Fellows Of Harvard College | Method of inducing and maintaining neuronal cells |
| US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| US5910487A (en) * | 1994-12-09 | 1999-06-08 | Genzyme Corporation | Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
| US5980886A (en) * | 1994-12-14 | 1999-11-09 | University Of Washington | Recombinant vectors for reconstitution of liver |
| US6107027A (en) | 1994-12-14 | 2000-08-22 | University Of Washington | Ribozymes for treating hepatitis C |
| US5770442A (en) * | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
| US6265212B1 (en) | 1995-06-15 | 2001-07-24 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| WO1997009420A2 (en) * | 1995-09-05 | 1997-03-13 | Celltech Therapeutics Limited | Dna sequences coding for a human metalloproteinase and variants thereof |
| WO1997017090A1 (en) | 1995-11-07 | 1997-05-15 | Baylor College Of Medicine | Adenovirus-mediated production of bioactive proteins by mammalian cells and animals |
| DE69736227D1 (en) * | 1996-04-25 | 2006-08-10 | Takeda Pharmaceutical | Matrix-metalloprotease |
| US6020191A (en) * | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
| DK0975771T3 (da) | 1997-04-18 | 2007-10-22 | Biogen Idec Inc | Fusionsproteiner af TGF-beta-receptortype II og immunoglobulins konstante region |
| US5922576A (en) | 1998-02-27 | 1999-07-13 | The John Hopkins University | Simplified system for generating recombinant adenoviruses |
| US6436393B1 (en) * | 1998-04-29 | 2002-08-20 | Guadalupe Bilbao | Adenoviral vector encoding anti-apoptotic Bcl-2 gene and uses thereof |
-
2000
- 2000-09-14 DE DE1221490T patent/DE1221490T1/de active Pending
- 2000-09-14 HK HK03100272.6A patent/HK1049860B/en unknown
- 2000-09-14 EP EP00961245A patent/EP1221490B1/en not_active Expired - Lifetime
- 2000-09-14 AU AU73226/00A patent/AU7322600A/en not_active Abandoned
- 2000-09-14 JP JP2001525321A patent/JP4173663B2/ja not_active Expired - Fee Related
- 2000-09-14 DE DE60017924T patent/DE60017924T2/de not_active Expired - Lifetime
- 2000-09-14 ES ES00961245T patent/ES2183752T3/es not_active Expired - Lifetime
- 2000-09-14 WO PCT/MX2000/000035 patent/WO2001021761A2/es not_active Ceased
- 2000-09-14 CA CA002385538A patent/CA2385538C/en not_active Expired - Fee Related
- 2000-09-15 CO CO00069981A patent/CO5420199A1/es not_active Application Discontinuation
- 2000-09-15 AR ARP000104867A patent/AR025692A1/es active IP Right Grant
- 2000-09-15 PE PE2000000962A patent/PE20010610A1/es not_active Application Discontinuation
-
2002
- 2002-03-18 US US10/098,359 patent/US20030003077A1/en not_active Abandoned
-
2003
- 2003-12-01 US US10/724,292 patent/US8043855B2/en not_active Expired - Fee Related
-
2005
- 2005-02-24 US US11/064,504 patent/US7858368B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20040156827A1 (en) | 2004-08-12 |
| WO2001021761A2 (es) | 2001-03-29 |
| PE20010610A1 (es) | 2001-05-25 |
| US8043855B2 (en) | 2011-10-25 |
| JP4173663B2 (ja) | 2008-10-29 |
| EP1221490A2 (en) | 2002-07-10 |
| HK1049860B (en) | 2006-02-24 |
| DE60017924D1 (de) | 2005-03-10 |
| AU7322600A (en) | 2001-04-24 |
| US20030003077A1 (en) | 2003-01-02 |
| DE60017924T2 (de) | 2006-03-30 |
| EP1221490B1 (en) | 2005-02-02 |
| ES2183752T3 (es) | 2005-07-16 |
| CA2385538C (en) | 2007-11-06 |
| US7858368B2 (en) | 2010-12-28 |
| DE1221490T1 (de) | 2003-05-28 |
| WO2001021761A3 (es) | 2001-09-07 |
| CO5420199A1 (es) | 2004-07-30 |
| CA2385538A1 (en) | 2001-03-29 |
| JP2004500040A (ja) | 2004-01-08 |
| ES2183752T1 (es) | 2003-04-01 |
| US20050201984A1 (en) | 2005-09-15 |
| HK1049860A1 (en) | 2003-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Musch et al. | Induction of heat shock protein 70 protects intestinal epithelial IEC-18 cells from oxidant and thermal injury | |
| EP0559884B1 (fr) | Vecteurs recombinants viraux pour l'expression dans des cellules musculaires | |
| CA2265252C (en) | Angiogenic factor and use thereof in treating cardiovascular disease | |
| ES2306483T5 (es) | Prote�?na inhibidora de la ruta de señalización de wnt. | |
| Nishida et al. | Potential applications of gene therapy to the treatment of intervertebral disc disorders. | |
| BR9914643A (pt) | Vetores adeno-associados para expressão dofator viii por células alvo | |
| US12343420B2 (en) | Stabilized polyribonucleotide coding for an elastic fibrous protein | |
| Greish et al. | Silk-elastinlike protein polymer hydrogels for localized adenoviral gene therapy of head and neck tumors | |
| AR025692A1 (es) | VECTORES ADENOVIRALES RECOMBINANTES, UN PROCESO PARA SU MANUFACTURA, UNA COMPOSICIoN FARMACEUTICA QUE LOS COMPRENDE Y SU USO PARA LA MANUFACTURA DE UN MEDICAMENTO EN EL TRATAMIENTO DE DIVERSOS TIPOS DE FIBROSIS HEPÁTICA, RENAL, PULMONAR Y CICATRICES HIPERTROFICAS | |
| ES2331441T3 (es) | Dna que codifica dp-75 y un proceso para su uso. | |
| WO2024207617A1 (zh) | 重编程因子抗衰老mRNA组合物、制备方法及应用 | |
| FR2723588A1 (fr) | Adenovirus comprenant un gene codant pour la glutathion peroxydase | |
| ES2936383T3 (es) | Terapias basadas en transcriptasa inversa de la telomerasa para el tratamiento de afecciones asociadas con el infarto de miocardio | |
| ES2226597T1 (es) | Vectores recombinantes virales y no virales que contienen el gen humano de urokinasa del activador del plasminogeno y su utilizacion en el tratamiento de varios tipos de fibrosis hepatica, renal, pulmonar, pancreatica y cardiaca y cicatrices hipertroficas. | |
| FR2724320B1 (fr) | Nouvel implant pour le traitement des maladies acquises | |
| JP2006519614A (ja) | 悪性かつ形質転換した哺乳動物細胞を選択的に殺すペプチド | |
| US20020122789A1 (en) | Viral recombinant vectors for expression in muscle cells | |
| JPH11318467A (ja) | 短縮型ジストロフィン | |
| Aframian et al. | Using HSV-thymidine kinase for safety in an allogeneic salivary graft cell line | |
| DE60137137D1 (de) | Viren gegen hypoxische zellen und gewebe | |
| AR077577A2 (es) | Polipeptidos relacionados con cancer de colon humano, polinucleotidos que lo codifican, vector, usos y composiciones farmaceuticas | |
| UY26342A1 (es) | Vectores adenovirales recombinantes y su utilidad en el tratamiento de diversos tipos de fibrosis hepática, renal, pulmonar y cicatrices hipertróficas | |
| US6099831A (en) | Viral recombinant vectors for expression in muscle cells | |
| BR0116014A (pt) | Polinucleotìdeo, cassete de expressão, vetor, medicamento, composição farmacêutica, uso de um polinucleotìdeo, animal transgênico, e, método de expressar um gene de interesse terapêutico in vivo | |
| JP2005539031A (ja) | 野生型または変異型ｅＮＯＳによる重症肢虚血の遺伝子療法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FG | Grant, registration |